If you've started noticing dark, coarse hair appearing on your chin, jaw, upper lip, or chest — and you have PCOS — you're not imagining it, and you're not alone.

This is one of the most distressing symptoms of polycystic ovary syndrome, not because it's dangerous in isolation, but because of what it does to how you feel in your own skin. The shame is real. The frustration is real. And unfortunately, so is the dismissal many women experience when they try to get answers.

This guide is here to change that.

We're going to walk through exactly what's happening hormonally, why PCOS causes excess facial and body hair, what the diagnosis process looks like, and — crucially — what actually helps. Root cause first. Always.

Hirsutism is the medical term for excessive growth of dark, coarse hair in women in areas typically associated with male hair patterns — including the face, chest, abdomen, and back.

It's not the same as the fine, light "peach fuzz" most women have. Hirsutism hair is terminal hair — darker, thicker, and more visible. It grows in places driven by androgen hormones, which is why it's so closely tied to conditions like PCOS.

Globally, hirsutism affects between 5–10% of women of reproductive age [Escobar-Morreale HF, NEJM, 2018]. In women with PCOS, the figure is significantly higher — estimates suggest up to 70–80% of women with PCOS experience some degree of unwanted hair growth [Lizneva D et al., Fertility and Sterility, 2016].

You're not in a small, unlucky minority. This is one of the most common presentations of PCOS — and it deserves a proper explanation.

PCOS causes excess facial and body hair because elevated androgen levels — particularly testosterone and DHEA-S — stimulate hair follicles in androgen-sensitive areas to produce coarser, darker terminal hair.

Here's what's actually happening at the follicle level.

In women without PCOS, androgens are present but in relatively low amounts. They influence hair growth in some areas, but they don't dominate. In women with PCOS, the ovaries and adrenal glands often produce androgens in excess — a state called hyperandrogenism.

These elevated androgens interact with androgen receptors in the hair follicle. When they do, they trigger a process called follicular miniaturisation in reverse — instead of the follicle shrinking (as it does in scalp hair loss), it grows. Vellus hairs — the soft, colourless ones — transform into terminal hairs: dark, thick, and visibly coarse.

The cruel irony of PCOS? The same androgen excess that causes unwanted hair on the face and body can simultaneously cause hair thinning on the scalp. Two opposite effects, one hormonal driver.

Understanding this mechanism matters because it changes the treatment approach. Managing symptoms at the surface (shaving, waxing, threading) addresses the result. Addressing androgen excess addresses the cause.

The three androgens most commonly elevated in PCOS-related hirsutism are:

• Testosterone — the most widely known androgen, produced primarily in the ovaries and adrenal glands
• DHEA-S (dehydroepiandrosterone sulphate) — largely produced by the adrenal glands; elevated in a significant subset of PCOS women
• Androstenedione — a precursor that converts to testosterone in peripheral tissues

It's worth knowing that not all PCOS women have the same androgen profile. Some have markedly elevated total testosterone. Others have elevated free testosterone (the biologically active form) with a normal-looking total testosterone — because low SHBG (sex hormone-binding globulin), also common in PCOS, means more testosterone is unbound and active [Pasquali R et al., Journal of Clinical Endocrinology & Metabolism, 2006].

This is why a standard testosterone result that looks "normal" doesn't always tell the full story. If you've been told your bloods are fine but you're experiencing hirsutism, this is worth discussing with a clinician who understands PCOS.

Hirsutism typically presents as dark, coarse hair growth on the face (chin, upper lip, cheeks), neck, chest, abdomen, and inner thighs — areas where androgen-sensitive follicles are most concentrated.

Specific signs to look for:

• Dark or thick hair on the upper lip, chin, jaw, or sideburn area
• Hair growth on the chest, around the nipples, or between the breasts
• Hair on the abdomen, particularly a line from navel to pubic area (linea nigra hair)
• Coarse hair on the upper back or lower back
• Hair on the inner thighs or buttocks

Hirsutism is typically scored clinically using the Ferriman-Gallwey scale, which assesses hair growth across nine body areas on a 0–4 scale. A total score above 8 in European women, or above 6 in East Asian women, is generally considered diagnostic of hirsutism [Hatch R et al., American Journal of Obstetrics and Gynecology, 1981].

It's important to note that hirsutism exists on a spectrum, and symptoms can vary significantly between individuals. There is no threshold below which the experience isn't valid.

While PCOS is the most common cause of hirsutism — accounting for approximately 72–82% of cases [Escobar-Morreale HF, NEJM, 2018] — it's not the only one.

Other causes include:

• Idiopathic hirsutism — elevated androgen sensitivity in the hair follicle without elevated serum androgens; accounts for around 6–15% of hirsutism cases
• Non-classic congenital adrenal hyperplasia (NCAH) — a genetic condition affecting cortisol production; important to rule out as it can present identically to PCOS
• Androgen-secreting tumours — rare, but important to exclude, particularly if hirsutism is severe and rapid in onset
• Cushing's syndrome — excess cortisol production leading to androgen elevation
• Certain medications — including valproate, danazol, some corticosteroids, and cyclosporin

This is why a thorough diagnostic workup matters. Assuming PCOS without ruling out other causes can mean missing something clinically significant.

Diagnosing PCOS as the cause of hirsutism involves ruling out other causes through blood tests, physical examination, and ultrasound — alongside applying the Rotterdam criteria for PCOS itself.

The diagnostic process typically includes:

• Medical and symptom history — onset, progression, medications, family history
• Physical examination — including assessment of hair distribution and pattern, skin changes such as acne or acanthosis nigricans (skin darkening at the neck or underarms, a sign of insulin resistance)
• Blood tests including:
  • Total and free testosterone
  • DHEA-S
  • SHBG
  • 17-hydroxyprogesterone (to rule out NCAH)
  • LH and FSH ratio
  • Fasting insulin and glucose (to assess insulin resistance)
  • Thyroid function (TSH and T4)
  • Prolactin
• Pelvic ultrasound — transvaginal where appropriate, to assess ovarian morphology

PCOS itself is diagnosed using the Rotterdam criteria, which requires at least two of the following three features [Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Human Reproduction, 2004]:

1. Oligo- or anovulation (irregular or absent periods)
2. Clinical or biochemical signs of hyperandrogenism (including hirsutism)
3. Polycystic ovarian morphology on ultrasound

One critical point: you do not need to have polycystic ovaries on ultrasound to be diagnosed with PCOS. And your blood tests do not need to be dramatically abnormal. The condition is broader than its name suggests.

Treatment for PCOS-related hirsutism falls into two main categories: addressing androgen excess at the root cause, and managing existing hair growth symptomatically.

The most effective approach combines both.

Insulin sensitivity is one of the most important levers for reducing androgen production in PCOS.

Here's why. In many women with PCOS, elevated insulin stimulates the ovaries to produce more androgens — particularly testosterone. This is why PCOS is often described as a metabolic condition as much as a reproductive one [Dunaif A, Endocrine Reviews, 1997].

Supporting insulin sensitivity through nutrition, movement, and targeted supplementation can meaningfully reduce androgen levels over time — and with that, slow the progression of hirsutism.

Key evidence-backed approaches include:

• Reducing refined carbohydrate and sugar load — not through restriction, but through blood sugar stability. Prioritising protein, fibre, and healthy fats at meals moderates the insulin response.
• Resistance training — improves insulin sensitivity in muscle tissue and has been shown to reduce androgen levels in women with PCOS [Kogure GS et al., Medicine & Science in Sports & Exercise, 2016]
• Myo-inositol supplementation — one of the most studied natural approaches for PCOS. Myo-inositol is a naturally occurring compound involved in insulin signalling. Women with PCOS often have impaired inositol metabolism, and supplementation has been shown to reduce fasting insulin, improve ovulation, and reduce androgen levels [Unfer V et al., Gynecological Endocrinology, 2017]

This is where MyOva's Hair, Skin & Nails supplement becomes genuinely relevant — not as a shortcut, but as targeted nutritional support for the mechanisms that drive hirsutism in PCOS.

The formula includes myo-inositol alongside a carefully selected range of nutrients known to support hormonal balance, skin health, and hair quality:

• Zinc — plays a direct role in reducing 5-alpha reductase activity, the enzyme that converts testosterone to its more potent form, DHT. Lower DHT means less androgen stimulation at the hair follicle [Stamatiadis D et al., British Journal of Dermatology, 1988]
• Vitamin A — involved in skin cell turnover and sebum regulation, both of which are disrupted in androgen excess
• Biotin (D-Biotin) — supports keratin infrastructure and is commonly depleted in women with hormonal dysregulation
• Vitamin C and Trans-Resveratrol — contribute to collagen synthesis and have anti-inflammatory and antioxidant effects relevant to the inflammatory profile of PCOS
• Grape Seed Extract and Hyaluronic Acid — support skin integrity and hydration
• Selenium (L-Selenomethionine) — involved in thyroid hormone conversion; thyroid dysfunction can compound androgen-related symptoms
• Lactobacillus acidophilus — emerging evidence suggests gut microbiome diversity affects oestrogen metabolism and androgen clearance [Qi X et al., Journal of Clinical Endocrinology & Metabolism, 2019]

It's not a magic fix. But it gives your body what it's often missing — the micronutritional foundation to support the hormonal processes that PCOS disrupts. That's a meaningful distinction from generic beauty supplements.

For women who need or want pharmaceutical support, there are well-established options:

Oral contraceptive pill (OCP) Combined oral contraceptives reduce LH-driven androgen production and increase SHBG — meaning more testosterone is bound and less is biologically active. They're often the first-line medical treatment for hirsutism, though they don't address the underlying metabolic driver.

Spironolactone An aldosterone antagonist that also blocks androgen receptors at the hair follicle. Evidence supports its efficacy for hirsutism, particularly at doses of 100–200mg per day [Brown J et al., Cochrane Database of Systematic Reviews, 2009]. Often used alongside the OCP.

Metformin An insulin-sensitising medication typically prescribed for type 2 diabetes but widely used in PCOS. By improving insulin sensitivity, it reduces the insulin-driven stimulation of androgen production. Particularly beneficial for women with confirmed insulin resistance.

Eflornithine (Vaniqa cream) A topical treatment that inhibits an enzyme required for hair growth. It doesn't remove existing hair but slows regrowth. Often used alongside laser treatment.

GnRH agonists Used in more severe or treatment-resistant cases, these suppress ovarian androgen production directly. Generally reserved for specific clinical scenarios due to side effects.

Medical and nutritional approaches take time — typically 6–12 months before significant hair reduction is visible, because hair growth cycles are slow. In the meantime, and as ongoing management, hair removal options are a legitimate part of the plan.

Laser hair removal Currently the most effective long-term option for hirsutism. Targets the pigment in the hair follicle with concentrated light, damaging the follicle and reducing regrowth over multiple sessions.

Important to know if you have PCOS: you may need more sessions than average. Because elevated androgens can continue to activate dormant follicles, new hair growth can occur even after treatment. Managing androgen levels alongside laser treatment gives the best long-term results.

Laser works best on darker hair with sufficient contrast against skin. Advances in technology mean it's now effective across a much wider range of skin tones than older systems.

Electrolysis The only FDA-cleared method of permanent hair removal. Works on all hair and skin types. More time-intensive per session than laser, but highly effective for stubborn or light-coloured hairs that don't respond well to laser.

Threading, waxing, and shaving None of these cause hair to grow back thicker — that's a myth. They remove hair at the surface and don't affect the follicle or androgen sensitivity. They're practical, cost-effective tools for managing day-to-day hair growth while longer-term approaches take effect.

Most women with PCOS-related hirsutism see meaningful improvement within 6–12 months of consistent treatment — whether medical, nutritional, or a combination of both.

Hair growth is slow. The full hair cycle — from growth phase (anagen) through rest (catagen) to shedding (telogen) — takes months. This is why treatments that reduce androgens don't show visible results immediately.

A realistic timeline looks something like this:

• Months 1–3: Hormonal changes begin internally; hair growth rate may slow slightly
• Months 3–6: Reduction in new coarse hair growth; existing hair begins to thin with continued treatment
• Months 6–12: More visible improvement in hirsutism score; significant reduction in some women

Patience here isn't passive. It's informed. Knowing that the mechanism is working even when you can't see it yet makes it easier to stay consistent.

You can slow the progression of PCOS-related hirsutism by managing the hormonal drivers — particularly insulin resistance and androgen excess — earlier rather than later.

This is one of the clearest arguments for taking PCOS seriously at diagnosis rather than waiting for symptoms to worsen.

Practical steps that make a meaningful difference:

• Prioritise blood sugar stability at every meal — not as a diet, but as a long-term metabolic strategy
• Build muscle through resistance training — muscle tissue is one of the most powerful sites of insulin clearance in the body
• Support your nutritional foundations — deficiencies in zinc, selenium, and B vitamins are common in PCOS and compound androgen-related symptoms
• Manage stress — chronic cortisol elevation drives adrenal androgen production; nervous system regulation isn't optional for PCOS
• Review any medications that may be exacerbating androgen activity with a clinician who understands PCOS fully

None of this is about being perfect. It's about reducing the hormonal burden consistently enough, over time, that your body has a chance to recalibrate.

No. Hirsutism affects an estimated 70–80% of women with PCOS, but not all. The degree of androgen sensitivity varies between individuals, so two women with the same hormone levels can have very different hair growth experiences. Absence of hirsutism doesn't rule out PCOS.

For women with PCOS and insulin resistance, weight changes can influence androgen levels — but framing this as a simple cause-and-effect is reductive. The research on insulin sensitivity, androgen production, and body composition in PCOS is more nuanced than "lose weight, fix hormones." Supporting metabolic health matters. The number on the scale is one data point, not the whole picture [Kiddy DS et al., Clinical Endocrinology, 1992].

Hair follicles that have already been converted from vellus to terminal don't automatically reverse when androgens normalise. This is why hair removal treatments (laser or electrolysis) are often needed alongside hormonal management — the two approaches work on different parts of the problem. Treating androgen excess prevents new growth; hair removal addresses what's already there.

Yes. Shaving does not cause hair to grow back thicker, darker, or faster — this is a myth rooted in perception rather than physiology. The blunt cut of a shaved hair feels coarser as it regrows, but the follicle itself is unchanged. Shave if it helps you feel more comfortable while longer-term approaches take effect.

Ask for: total and free testosterone, DHEA-S, SHBG, 17-hydroxyprogesterone (to rule out NCAH), LH, FSH, fasting insulin and glucose, and thyroid function. If your GP is reluctant, a private PCOS-focused hormone panel is a reasonable next step.

This guide would be incomplete without saying this directly.

Excess facial hair carries a disproportionate emotional weight for many women with PCOS. It's visible in a way that irregular cycles or insulin resistance aren't. It intersects with identity, femininity, and social confidence in ways that are hard to articulate and easy to feel alone with.

You're not being dramatic. The research reflects this — hirsutism has been shown to significantly impact quality of life, self-esteem, and psychological wellbeing in women with PCOS [Dokras A et al., Fertility and Sterility, 2011].

What helps is not being told to accept it or not to care. What helps is having a clear explanation of what's driving it, a credible plan for addressing it, and the knowledge that improvement — real, measurable improvement — is possible.

Your body is trying to tell you something. The hirsutism is a signal, not a verdict.

• What Is PCOS? A Complete Guide to Polycystic Ovary Syndrome
• PCOS and Hair Removal: What Actually Works
• PCOS and Hair Loss: Why It Happens and What Helps
• Insulin Resistance and PCOS: The Connection Most Women Aren't Told About
• PCOS and Acne

1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. New England Journal of Medicine. 2018;375(1):54-64.
2. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility and Sterility. 2016;106(1):6-15.
3. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 2006;91(4):1240-1246.
4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004;19(1):41-47.
5. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 1997;18(6):774-800.
6. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. American Journal of Obstetrics and Gynecology. 1981;140(7):815-830.
7. Kogure GS, Miranda-Furtado CL, Silva RC, et al. Resistance exercise impacts lean muscle mass in women with polycystic ovary syndrome. Medicine & Science in Sports & Exercise. 2016;48(4):589-598.
8. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological Endocrinology. 2017;28(7):509-515.
9. Stamatiadis D, Bulteau-Portois MC, Mowszowicz I. Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. British Journal of Dermatology. 1988;119(5):627-632.
10. Qi X, Yun C, Sun L, et al. Gut microbiota–bile acid–interleukin-18 signalling chain links hyperglycaemia to occurrence of gestational diabetes mellitus. Journal of Clinical Endocrinology & Metabolism. 2019;104(11):5633-5644.
11. Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database of Systematic Reviews. 2009;(2):CD000194.
12. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical Endocrinology. 1992;36(1):105-111.
13. Dokras A, Clifton S, Futterweit W, Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstetrics & Gynecology. 2011;117(1):145-152.